samedan logo
 
 
 
spacer
home > ebr > autumn 2002 > biotech in europe - a genzyme perspective
PUBLICATIONS
European Biopharmaceutical Review

Biotech in Europe - A Genzyme Perspective

Dr Tambuyzer, in your opinion, what are the main opportunities for US biotechnology companies operating in Europe? The first opportunity is that population-wise, Europe is the largest market for biopharmaceuticals in the world. One of the other important benefits is that Europe has a very high-quality research base providing the groundwork for a variety of innovative products and technologies. It is significant, however, that Europe has less drive and less experience than the US in converting this expertise into products and services for commercialisation. This provides strong business-oriented companies with the opportunity to forge many high-level research, clinical and/or technological collaborations in an environment that is less competitive than in the US.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
An Interview with Dr Erik Tambuyzer, Vice President, Corporate Affairs Europe of the Genzyme Corporation

Dr Erik Tambuyzer is Genzyme Corporation's Vice President Corporate Affairs Europe, and a member of the European Executive Board of Genzyme. Starting his professional career at Baxter Health Care in 1977, he pursued his career at Innovi NV in Belgium from where he co-founded the biotech company Innogenetics NV in 1985, becoming General Manager. In 1992, Dr Tambuyzer joined Genzyme as Vice President Diagnostics and Genetics Europe. In October 2000, he was elected Chairman of the Board of EuropaBio - the European Association for Bioindustries - as well as Founder and Chairman of the Ethics Working Group.
Dr Tambuyzer is Vice-Chairman of EPPOSI, the European Platform for Patients' Organisations, Science & Industry. He is also on the Board of EBE, a specialised group within EFPIA, the European pharmaceutical industry organisation. He advises international journals and is Chairman of the Advisory Board of the Life Sciences Fund of Dresdner Kleinwort Capital. Dr Tambuyzer is a Bio-Engineer and holds a PhD in bio-industrial sciences from the University of Leuven in Belgium..

spacer
Dr Erik Tambuyzer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Owen Mumford Launches New 2-Step Single-Use Auto-Injector Platform Aidaptus®

OXFORD, England, 22nd September - Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd. has launched its new Aidaptus® auto-injector platform following successful completion of development. Aidaptus is a 2-step, spring-powered, single use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features stopper sensing technology with a self-adjusting plunger that automatically adapts to the individual stopper positions and different fill volumes in each syringe, with no change parts required. The auto-injector is available with two different spring strengths to accommodate a variety of drug viscosities.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement